JP2017500017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500017A5 JP2017500017A5 JP2016532136A JP2016532136A JP2017500017A5 JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5 JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5
- Authority
- JP
- Japan
- Prior art keywords
- culture
- cells
- liters
- item
- viable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 93
- 210000004027 cell Anatomy 0.000 claims description 67
- 230000001186 cumulative effect Effects 0.000 claims description 28
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims description 11
- 238000010899 nucleation Methods 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 230000010412 perfusion Effects 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002699 waste material Substances 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 102100023961 ADP-ribosylation factor-like protein 2-binding protein Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 101000757692 Homo sapiens ADP-ribosylation factor-like protein 2-binding protein Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000934823 Homo sapiens Barttin Proteins 0.000 claims description 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 229940003504 avonex Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229950005751 ocrelizumab Drugs 0.000 claims description 2
- 239000012716 precipitator Substances 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919629P | 2013-12-20 | 2013-12-20 | |
| US61/919,629 | 2013-12-20 | ||
| PCT/US2014/071701 WO2015095809A1 (en) | 2013-12-20 | 2014-12-19 | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000268A Division JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500017A JP2017500017A (ja) | 2017-01-05 |
| JP2017500017A5 true JP2017500017A5 (enExample) | 2018-02-08 |
Family
ID=52347449
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532136A Withdrawn JP2017500017A (ja) | 2013-12-20 | 2014-12-19 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2020000268A Withdrawn JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2022197095A Pending JP2023022317A (ja) | 2013-12-20 | 2022-12-09 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000268A Withdrawn JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2022197095A Pending JP2023022317A (ja) | 2013-12-20 | 2022-12-09 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20160289633A1 (enExample) |
| EP (1) | EP3083933A1 (enExample) |
| JP (3) | JP2017500017A (enExample) |
| WO (1) | WO2015095809A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| TWI743024B (zh) | 2014-06-06 | 2021-10-21 | 美商健臻公司 | 灌注培養方法及其用途 |
| TWI707949B (zh) | 2014-06-09 | 2020-10-21 | 美商健臻公司 | 種子罐培養法（ｓｅｅｄ ｔｒａｉｎ ｐｒｏｃｅｓｓｅｓ）及其用途 |
| EP3371297A1 (en) * | 2015-11-02 | 2018-09-12 | Ares Trading S.A. | Methods for modulating production profiles of recombinant proteins in perfusion mode |
| US11104875B2 (en) | 2016-01-26 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Linked perfusion to continuous-flow stirred-tank reactor cell culture system |
| EP3504315A4 (en) | 2016-08-27 | 2020-04-15 | 3D Biotek, LLC | BIOREACTOR |
| EP3681989A1 (en) * | 2017-09-15 | 2020-07-22 | Bristol-Myers Squibb Company | Online biomass capacitance monitoring during large scale production of polypeptides of interest |
| KR20250151558A (ko) | 2017-10-06 | 2025-10-21 | 론자 리미티드 | 라만 분광법을 사용하는 세포 배양의 자동 제어 |
| HUE058924T2 (hu) | 2017-10-16 | 2022-09-28 | Regeneron Pharma | Perfúziós eljárások |
| MA50911A (fr) * | 2017-11-13 | 2020-09-23 | Amgen Inc | Procédés de production de produits protéiniques |
| CA3082507A1 (en) * | 2017-12-11 | 2019-06-20 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
| CN110241012B (zh) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用 |
| CA3098565A1 (en) * | 2018-04-29 | 2019-11-07 | Claire G. ZHANG | Scalable clarification process for recombinant aav production |
| US12071607B2 (en) | 2018-06-01 | 2024-08-27 | Lonza Ltd. | Midscale model for organic growth and phasing |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
| US20210403971A1 (en) * | 2018-11-02 | 2021-12-30 | Kyowa Kirin Co., Ltd. | Method for preparing liquid medium |
| EP3914696A4 (en) * | 2019-01-25 | 2022-12-14 | Biogen MA Inc. | SEED CULTIVATION METHOD FOR THE PRODUCTION OF AAV |
| SG11202111135PA (en) * | 2019-04-11 | 2021-11-29 | Merck Patent Gmbh | Cell culture media comprising keto acids |
| US20220259554A1 (en) * | 2019-07-16 | 2022-08-18 | Innovent Biologics (Suzhou) Co., Ltd. | Cell culture method and application thereof based on high-density and continuous inoculation |
| EP4007808A1 (en) * | 2019-08-01 | 2022-06-08 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
| CA3201327A1 (en) * | 2020-12-08 | 2022-06-16 | Partner Therapeutics, Inc. | Manufacture of granulocyte macrophage-colony stimulating factor |
| CN117222668A (zh) | 2021-05-03 | 2023-12-12 | 勃林格殷格翰国际有限公司 | 制备spesolimab的方法 |
| WO2023114897A2 (en) | 2021-12-15 | 2023-06-22 | Homology Medicines, Inc. | Methods and compositions for the production of adeno-associated virus |
| CN119137263A (zh) * | 2022-03-07 | 2024-12-13 | 奥特吉尼克斯制药公司 | 改进的分批aav产生系统和方法 |
| AU2023338683A1 (en) * | 2022-09-06 | 2025-03-13 | Amgen Inc. | Lean perfusion cell culture methods |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP1026240A3 (en) | 1988-09-02 | 2004-04-07 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| US7125841B2 (en) | 2000-11-14 | 2006-10-24 | The University Of Texas Systems | Mutant human factor IX with an increased resistance to inhibition by heparin |
| WO2002050251A2 (en) * | 2000-12-20 | 2002-06-27 | Bayer Pharmaceuticals Corporation | A device and method for seed-train expansion of mammalian cells |
| KR20040039328A (ko) | 2001-09-04 | 2004-05-10 | 메르크 파텐트 게엠베하 | 변형된 펙터 ⅸ |
| WO2003071271A1 (en) | 2002-02-21 | 2003-08-28 | Tokyo Gas Company Limited | Test agents for evaluating pharmacological effect of drug, and method and reagents for screening drug having excellent administration effect and/or little side effect from among drugs comprising enzymes, enzyme inhibitors or receptor ligands and/or produrgs thereof |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| SI1720972T1 (sl) * | 2004-03-05 | 2014-06-30 | Dsm Ip Assets B.V. | Postopek kultiviranja celic s kontinuiranim škropljenjem in spreminjanjem tangencialnega toka |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| EP2423307A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
| SG174804A1 (enExample) * | 2006-09-13 | 2011-10-28 | Abbott Lab | |
| US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
| CA2702363A1 (en) | 2007-10-15 | 2009-04-23 | The University Of North Carolina At Chapel Hill | Human factor ix variants with an extended half life |
| EP2288622A4 (en) | 2008-04-16 | 2012-04-18 | Bayer Healthcare Llc | FACTOR IX MODIFIED POLYPEPTIDES AND USES THEREOF |
| KR20110015551A (ko) | 2008-04-16 | 2011-02-16 | 바이엘 헬스케어 엘엘씨 | 제ｉｘ인자의 부위-지정 변형 |
| WO2009130198A2 (en) | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| KR20110016899A (ko) * | 2008-04-23 | 2011-02-18 | 심포젠 에이/에스 | 폴리클로날 단백질을 제조하는 방법 |
| AU2009257336B2 (en) * | 2008-06-13 | 2016-01-28 | Janssen Biotech, Inc. | Methods for obtaining high viable cell density in mammalian cell culture |
| NZ703153A (en) | 2009-12-06 | 2015-02-27 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| JP2013517776A (ja) * | 2010-01-25 | 2013-05-20 | ベントリア・バイオサイエンス | タンパク質の生成を改善するための方法および組成物 |
| UA126265C2 (uk) | 2010-07-09 | 2022-09-14 | Байовератів Терапьютікс Інк. | Поліпептид фактора іх і спосіб його застосування |
| EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
| CN103415610B (zh) | 2011-03-18 | 2016-10-19 | 通用电气健康护理生物科学股份公司 | 用于培养细胞的弹性袋 |
| CA2952347A1 (en) | 2011-07-01 | 2013-01-10 | Amgen Inc. | Mammalian cell culture |
| WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
-
2014
- 2014-12-19 WO PCT/US2014/071701 patent/WO2015095809A1/en not_active Ceased
- 2014-12-19 JP JP2016532136A patent/JP2017500017A/ja not_active Withdrawn
- 2014-12-19 US US15/038,698 patent/US20160289633A1/en not_active Abandoned
- 2014-12-19 EP EP14827357.6A patent/EP3083933A1/en active Pending
-
2020
- 2020-01-06 JP JP2020000268A patent/JP2020054388A/ja not_active Withdrawn
-
2022
- 2022-12-09 JP JP2022197095A patent/JP2023022317A/ja active Pending
-
2025
- 2025-01-17 US US19/027,281 patent/US20250382568A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500017A5 (enExample) | ||
| KR101644954B1 (ko) | 배양 동안 락테이트의 축적을 감소시키는 방법 및 폴리펩타이드를 생산하는 방법 | |
| CN105378086B (zh) | 用于控制重组蛋白质中c端赖氨酸、半乳糖和唾液酸含量的制造方法 | |
| US11912739B2 (en) | Sterile chromatography and manufacturing processes | |
| US12480947B2 (en) | Method for generating high affinity antibodies | |
| KR101591671B1 (ko) | 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법 | |
| US9908932B2 (en) | Methods of shifting an isoelectric profile of a protein product and uses thereof | |
| SI2904092T1 (en) | Ingredients and procedures for the production of glycoproteins | |
| CN115873904A (zh) | 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞 | |
| JP6108170B2 (ja) | 細胞培養用培地 | |
| HRP20250491T1 (hr) | Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina | |
| US20160108357A1 (en) | Methods of culturing a cell | |
| Aalilouch et al. | Monoclonal Antibody Production Using Hybridoma Technology: Advances, Challenges and Applications | |
| AU2017393059B2 (en) | Method for producing corneal epithelial cell mass | |
| RU2786078C2 (ru) | Способы стерильной хроматографии и производства | |
| Bodeus et al. | In Vitro Production of Rat Monoclonal Antibodies | |
| US11254964B1 (en) | Cell culture methods for increased cell viability | |
| Dewan | Evaluation of Zinc Compounds and LongTM R3 IGF-I as Alternatives for Insulin in Serum-free Media to Support Growth and Productivity of an Sp2/0 Cell Line | |
| CN120137879A (zh) | 一种高效率正确表达具有非对称结构抗体的细胞培养方法 | |
| CN117126858A (zh) | 一种用于预防和/或治疗肿瘤的抗TGFβ的人源化纳米抗体 | |
| JP5466326B1 (ja) | ラットモノクローナル抗体作製用パートナー細胞およびそのスクリーニング方法 | |
| CN117230078A (zh) | 一种抗TGFβ的人源化纳米抗体及其制备方法和用途 | |
| CN102234641A (zh) | 一种快速获取特异性人源抗体可变区基因序列的方法 | |
| Suba Dharshanan | Development, expression and characterization of humanized anti-c2 monoclonal antibody/Suba Dharshanan A/L Panja Bernam | |
| NZ616727B2 (en) | Method for producing sheet-like pancreatic islet |